Despite the use of preferred controller therapies (including inhaled corticosteroids (ICS) with or without additional long-acting β2-agonists (LABAs)), a large proportion of patients with asthma have poor disease control, leaving them at risk of recurring symptoms and episodes of asthma exacerbations and worsening [1, 2]. Such problems can be triggered by many different environmental factors including pollutants, respiratory infections or allergens [3]. They may occur sporadically, but are often determined by the seasons, mirroring seasonal patterns of allergen exposure and prevalence of respiratory viral infection [3, 4]. In adults with symptomatic severe asthma despite inhaled corticosteroid/long-acting β2-agonist therapy, tiotropium add-on therapy reduces seasonal peaks of asthma worsening, providing a year-round benefit http://bit.ly/2m4LGuH

中文翻译：

---

噻托溴铵附加疗法可降低成人有症状的重度哮喘患者哮喘恶化的季节性高峰

尽管使用了首选的控制疗法（包括吸入性皮质类固醇 (ICS)，有或没有额外的长效 β2-激动剂 (LABA)），但很大一部分哮喘患者的疾病控制不佳，使他们面临症状和发作复发的风险哮喘发作和恶化 [1, 2]。此类问题可能由许多不同的环境因素引发，包括污染物、呼吸道感染或过敏原 [3]。它们可能偶尔发生，但通常由季节决定，反映了过敏原暴露的季节性模式和呼吸道病毒感染的流行 [3, 4]。尽管吸入皮质类固醇/长效 β2 受体激动剂治疗后仍有症状的重度哮喘成人，噻托溴铵附加治疗可减少哮喘恶化的季节性高峰，提供全年益处 http://bit.ly/2m4LGuH